We are very pleased to announce Kim Popovits as the winner of this year’s Ferolyn Powell award.
Established in 2015 to honor the memory of Ferolyn Powell, a pioneer in the medtech industry and a mentor to entrepreneurs, MedtechWomen’s Ferolyn Powell award recognizes medtech leaders who embody persistence, passion, dedication to innovation and patients, and commitment to mentoring.
“Kim is one of those rare leaders who sets standards in multiple arenas – and the rest of us try to follow them, not because we have to, but because we want to,” said Deborah Kilpatrick, Ph.D., MedtechWomen co-founder and CEO of Evidation Health. “The fact that she is this kind of leader – the kind that others emulate – is exactly why Kim is receiving the Ferolyn Powell award this year.”
For the past 30 years Kim Popovits has worked on improving the health and lives of men and women worldwide through her career in the biopharmaceutical industry. She currently serves as Genomic Health’s chairman of the Board, chief executive officer, and president, leading a company revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers. The company’s Oncotype DX tests address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.
She has also held leadership roles at Genentech as Senior Vice President, Marketing and Sales, and American Critical Care, a Division of American Hospital Supply. In addition to her community service working with several non-profit organizations, Kim serves on the Boards of multiple organizations including the California Life Sciences Association, the Personalized Medicine Coalition, and the American Clinical Laboratory Association. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Advisor to the Healthcare Businesswomen’s Association (HBA). She is a graduate of Michigan State University.